Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: EZLibra who wrote (104)	8/11/1998 10:10:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 666

Davis: Very busy, and Netcom customers were actually shut out of SI for the past two days. I think you'll need to distill everything to threadbare facts and present them (if anyone in the thread objects, please say so..... this isn't the TCLN thread) here, one at a time. I'm not going to wade through posts in the TCLN thread, and I prefer public to private discussions. Checked on the background of the new CEO. He almost took Xytronyx (now Pacific Pharmaceuticals, correct?) to being delisted?? Market cap of 60M and almost no money? I'm always willing to have someone feed me a bargain. However, just because a physician in Texas says that TNT is great is no reason to bite. If you'll look at issues like BTRN, SIBI, and OSIP that are selling at near-book and which have potent science/infrastructures, you can understand why many of us don't have time to chase to Yahoo or to you for material that needs distillation. You'll need to present the good chunks, unadorned, and forget the chunks that float to the top of the PR cesspool. I'm certain that many here would like to hear the story, presented in a concise fashion. As you know, I'm leery of companies that have sustained the sort of funding hit that TCLN has endured. Again, if anyone in the thread objects, tell me to get lost. Davis.... you will have an extremely critical and capable audience here. The scientific manpower that can be SI-focused on a given issue is awesome. Given low-priced stocks where there is little coverage, that focus might be a bit harsh. Rick